This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
VTCN1 · Western blot design guide
VTCN1 Western Blot Planning Guide
Plan a VTCN1 Western blot around the catalog-observed 30.9 kDa band, image-backed A02821-3 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
VTCN1 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 30.9 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Bronchus | |
| Negative control | Adipose tissue |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 30.9 kDa |
| ⓘ | Localization | Cell membrane |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated VTCN1 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Bronchus |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A02821-3 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected VTCN1 Western Blot Band Size?
Use the product-observed 30.9 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 30.9 kDa | Matches the authoritative product WB observation. |
| 30.9 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected VTCN1 appearancePlan around 30.9 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 30.9 kDa; use this as the primary experimental expectation. |
| Calculated mass | 30.9 kDa from UniProt Q7Z7D3; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A02821-3. |
| Situation | Likely cause | Next action |
|---|---|---|
| 30.9 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing VTCN1 band
A02821-3 · VTCN1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for VTCN1 Western blot
🧪Use Bronchus as the first positive-control candidate and Adipose tissue as the HPA Not detected negative candidate.
Positive control: Bronchus (High)
Negative control: Adipose tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for VTCN1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bronchus | Reported tissue cells | High | Protein (HPA) | HPA → |
| Nasopharynx | Reported tissue cells | High | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced VTCN1 Western Blot Tips
Deeper troubleshooting and optimisation questions for VTCN1, answered from its protein features.
Which band should guide the blot?
Use 30.9 kDa, the observation attached to the authoritative A02821-3 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 30.9 kDa expectation.
Which positive control should I start with?
Start with Bronchus, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Adipose tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for VTCN1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A02821-3 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC10544262, PMC12783301, PMC4744569.
Boster reagents
VTCN1 Western Blot Reagents
Human/Mouse/Rat-reactive VTCN1 Western blot reagents with authoritative product imagery.
Real WB data
Anti-B7H4/VTCN1 Antibody Picoband®
Cat # A02821-3
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q7Z7D3
- Human Protein Atlas — VTCN1
- A02821-3 product record
- PMC10544262 — A Novel Gene Pair CSTF2/DPE2A Impacts Prognosis and Cell Cycle of Hepatocellular Carcinoma.
- PMC12783301 — HSP90AA1 restrains clear cell renal cell carcinoma progression by promoting CADM1 expression and suppressing the PI3K-AKT pathway through interaction with FBXO7.
- PMC4744569 — Loss of Peripheral Protection in Pancreatic Islets by Proteolysis-Driven Impairment of VTCN1 (B7-H4) Presentation Is Associated with the Development of Autoimmune Diabetes.